Form D · Biotechnology

Lenz Therapeutics, Inc.

Del Mar, CA · CIK 0001678518

Offering snapshot reported Mar 10, 2023 · SEC filing

Reported sold
$83.5M
Offering amount: $83.5M
Investors reported
27
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 6, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 10, 2023Initial$83,499,961No comparison27SEC filing
Nov 22, 2022Amendment$49,002,348$47,251,155vs Nov 9, 202045SEC filing
Nov 9, 2020Initial$1,751,193No comparison30SEC filing
Sep 14, 2020Initial$250,000No comparison25SEC filing
Jun 30, 2016Initial$3,399,989No comparison45SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-475519

Source: Form D, filed Mar 10, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Chris Dimitropoulos Director
Frederic Guerard Director
Fred Guerard Director
Gerald Horn Director, Executive
Stefan Larson Director
Mark Lester Director
James Mc Collum Director
Clare Ozawa Director
Zach Scheiner Director
Evert Schimmelpennink Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
445 Marine View Ave., Suite #320
Del Mar, CA, 92014